AC-262,536
Chemical compound
From Wikipedia, the free encyclopedia
AC-262536, also known as Accadrine, is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5 nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the levator ani muscle weight increase of testosterone, but only around 27% of its maximal effect on prostate gland weight.[1][2][3] It is an aniline SARM related to ACP-105 and vosilasarm (RAD140).[4] The drug was encountered as a novel designer drug by at least 2020.[5]
| |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H18N2O |
| Molar mass | 278.355 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Medical uses
Accadrine is not approved for any medical use by the Food and Drug Administration and is not available as a licensed pharmaceutical drug as of 2025.[6]
Pharmacology
Pharmacodynamics
Accadrine is selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist or partial agonist of the androgen receptor (AR).[7][4] This receptor is the biological target of endogenous androgens like testosterone and dihydrotestosterone (DHT) and of synthetic anabolic steroids like nandrolone and oxandrolone.[8][9][10][11] Accadrine shows high affinity for the AR, with a Ki value of 5 nM (relative to 29 nM for testosterone and 10 nM for DHT).[1][2][3]